Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends.

(co-)amorphous cohesiveness compressibility flowability olanzapine tablet

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
23 Jul 2022
Historique:
received: 01 07 2022
revised: 19 07 2022
accepted: 21 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

The work evaluates the stability of amorphous and co-amorphous olanzapine (OLZ) in tablets manufactured by direct compression. The flowability and the compressibility of amorphous and co-amorphous OLZ with saccharin (SAC) and the properties of the tablets obtained were measured and compared to those of tablets made with crystalline OLZ. The flowability of the amorphous and mostly of the co-amorphous OLZ powders decreased in comparison with the crystalline OLZ due to the higher cohesiveness of the former materials. The stability of the amorphous and co-amorphous OLZ prior to and after tableting was monitored by XRPD, FTIR, and NIR spectroscopies. Tablets presented long-lasting amorphous OLZ with enhanced water solubility, but the release rate of the drug decreased in comparison with tablets containing crystalline OLZ. In physical mixtures made of crystalline OLZ and SAC, an extent of amorphization of approximately 20% was accomplished through the application of compaction pressures and dwell times of 155 MPa and 5 min, respectively. The work highlighted the stability of amorphous and co-amorphous OLZ during tableting and the positive effect of compaction pressure on the formation of co-amorphous OLZ, providing an expedited amorphization technique, given that the process development-associated hurdles were overcome.

Identifiants

pubmed: 35893791
pii: pharmaceutics14081535
doi: 10.3390/pharmaceutics14081535
pmc: PMC9332588
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fundação para a Ciência e Tecnologia
ID : PTDC/CTM-BIO/3946/2014; SFRH/BD/137080/2018

Références

Pharmaceutics. 2013 Oct 25;5(4):570-90
pubmed: 24300563
Int J Pharm. 2021 May 1;600:120448
pubmed: 33675920
J Pharm Sci. 2017 Feb;106(2):579-588
pubmed: 27938895
Int J Pharm. 2013 May 1;448(1):320-6
pubmed: 23518365
Nature. 2001 Nov 29;414(6863):528-30
pubmed: 11734849
Int J Pharm. 2005 Sep 14;301(1-2):33-40
pubmed: 16040214
Pharmaceutics. 2021 Jan 27;13(2):
pubmed: 33514009
Int J Pharm. 2021 Jun 1;602:120649
pubmed: 33915186
Mol Pharm. 2019 Feb 4;16(2):825-833
pubmed: 30575400
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):873-81
pubmed: 23537574
Expert Opin Drug Discov. 2020 Jul;15(7):853-864
pubmed: 32290727
Eur J Pharm Biopharm. 2015 Oct;96:44-52
pubmed: 26197392
Drug Dev Ind Pharm. 2001 Sep;27(8):789-801
pubmed: 11699830
Pharmaceutics. 2021 Mar 15;13(3):
pubmed: 33804159
Eur J Pharm Biopharm. 2014 Apr;86(3):337-50
pubmed: 24075979
Pharm Dev Technol. 2000;5(4):485-94
pubmed: 11109248
Clin Pharmacokinet. 2007;46(5):359-88
pubmed: 17465637
ISRN Pharm. 2012;2012:195727
pubmed: 22830056
Mar Drugs. 2020 Feb 17;18(2):
pubmed: 32079246
Eur J Pharm Biopharm. 2018 Oct;131:25-32
pubmed: 30040997
AAPS PharmSciTech. 2019 Mar 18;20(4):144
pubmed: 30887140
Int J Pharm. 2021 Aug 10;605:120802
pubmed: 34144131
AAPS PharmSciTech. 2021 Jan 3;22(1):21
pubmed: 33389277
Eur J Pharm Sci. 2021 Mar 1;158:105667
pubmed: 33296711
Pharmaceutics. 2019 Dec 05;11(12):
pubmed: 31817454
Int J Pharm. 2013 Aug 30;453(1):65-79
pubmed: 22569230
Clin Pharmacokinet. 2015 Apr;54(4):325-57
pubmed: 25666353
Pharm Dev Technol. 2017 Feb;22(1):69-76
pubmed: 27050301
J Pharm Sci. 2015 Nov;104(11):3804-3813
pubmed: 26220285
Ther Adv Psychopharmacol. 2014 Feb;4(1):30-6
pubmed: 24490028
Pharmaceutics. 2022 May 02;14(5):
pubmed: 35631565
Int J Pharm. 2018 May 30;543(1-2):234-244
pubmed: 29621552
Int J Pharm. 2020 Oct 15;588:119716
pubmed: 32758593
J Pharm Biomed Anal. 2010 Aug 1;52(4):484-92
pubmed: 20167448
J Drug Deliv Sci Technol. 2021 Feb;61:
pubmed: 33717230
Int J Pharm. 2022 Mar 5;615:121475
pubmed: 35041914
Adv Drug Deliv Rev. 2016 May 1;100:116-25
pubmed: 26805787
Eur J Pharm Biopharm. 2018 Nov;132:112-126
pubmed: 30248394
J Pharm Sci. 1970 May;59(5):688-91
pubmed: 5446428
J Pharm Sci. 2019 Jan;108(1):476-484
pubmed: 30248335
J Pharm Sci. 2019 Apr;108(4):1396-1400
pubmed: 30448523
J Pharm Sci. 2014 Apr;103(4):1214-23
pubmed: 24765654
Int J Pharm. 2016 Dec 30;515(1-2):403-415
pubmed: 27771485

Auteurs

Nuno F da Costa (NF)

iMed.ULisboa-Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.

Rolf Daniels (R)

Department of Pharmaceutical Technology, Eberhard Karls University, Auf der Morgenstelle 8, D-72076 Tuebingen, Germany.

Ana I Fernandes (AI)

CiiEM-Interdisciplinary Research Center Egas Moniz, Instituto Universitário Egas Moniz, Monte de Caparica, 2829-511 Caparica, Portugal.

João F Pinto (JF)

iMed.ULisboa-Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.

Classifications MeSH